Stocktoria
LIGAND PHARMACEUTICALS INC LGND
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1992-11-18
LIGAND PHARMACEUTICALS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $268.1M | $167.1M | $131.3M | $196.2M | $241.5M |
| R&D expense | $81.2M | $21.4M | $24.5M | $36.1M | $32.1M |
| Operating income | $41.0M | -$22.6M | $11.9M | $3.0M | $103.9M |
| Interest expense | — | — | $656,000 | $1.8M | $19.6M |
| Income tax | $34.5M | $6.5M | $9.8M | $41.2M | -$4.1M |
| Net income | $124.5M | -$4.0M | $52.2M | -$33.4M | $57.1M |
| EPS (diluted) | $6.13 | $-0.22 | $2.94 | $-1.98 | $3.31 |
| Operating cash flow | $49.4M | $97.0M | $49.6M | $137.8M | $78.8M |
| Free cash flow | $48.9M | $95.2M | $46.1M | $119.9M | $70.0M |
| Cash & equivalents | $174.9M | $72.3M | $23.0M | $45.0M | $19.5M |
| Inventory | $9.1M | $14.1M | $24.0M | $13.3M | $27.3M |
| Total assets | $1.6B | $941.8M | $787.2M | $762.7M | $1.3B |
| Total liabilities | $543.4M | $111.3M | $86.3M | $165.2M | $476.4M |
| Shareholders' equity | $1.0B | $830.4M | $700.9M | $597.5M | $821.2M |
Source: SEC EDGAR filings · CIK 0000886163 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.